In December 2025, Genentech, part of the Roche Group, received U.S. FDA accelerated approval for Lunsumio VELO, a subcutaneous formulation of mosunetuzumab for adults with relapsed or refractory ...

Many doctors agree with the Food and Drug Administration’s recent decision to remove the black box warnings on at least some ...

The FDA approves a new subcutaneous formulation of amivantamab, enhancing treatment for advanced lung cancer with reduced administration time and improved safety.

Lunsumio Velo is supplied as a ready-to-use, preservative-free solution in single-dose vials containing 5mg/0.5mL and 45mg/mL.

Transparency International Bangladesh (TIB) has estimated that around Tk 250 crore was siphoned off through corruption in ...

Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...

The US Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio VELO (mosunetuzumab), from Roche, as a ...

US FDA approves Roche’s Lunsumio VELO for subcutaneous use in relapsed or refractory follicular lymphoma: Basel Tuesday, December 23, 2025, 13:00 Hrs [IST] Roche announced that ...

Genentech, a subsidiary of the Roche Group, has received the US FDA accelerated approval for Lunsumio VELO SC formulation to ...

LAPIX Therapeutics, Inc. (“LAPIX”), a clinical-stage biopharmaceutical company developing first-in-class, orally delivered immune-tolerance-restoring therapies, announced today that the first patient ...

With only two products on the market, Inner Balance is offering an alternative to long-standing treatment models in hormone ...

SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Positive Results for SGX302 in Cohort 3 of Phase 2a Psoriasis Trial ...